Navigation Links
Angelman Syndrome Foundation Takes Major Step Toward Furthering Research Efforts
Date:8/6/2009

The Angelman Syndrome Foundation, www.angelman.org, announced the formation of the Angelman Treatment and Research Institute (ATRI), which will direct the organization's rapidly increasing research funding. The ATRI will also serve as a hub for more than 30 organizations, researchers and scientists worldwide to share discoveries and treatments for this neuro-genetic disorder. The announcement of the ATRI was made during the Angelman Syndrome Foundation's biennial conference in Orlando, Fla.

Orlando, FL (PRWEB) August 6, 2009 -- The Angelman Syndrome Foundation, www.angelman.org, announced the formation of the Angelman Treatment and Research Institute (ATRI), which will direct the organization's rapidly increasing research funding.

News Facts Related to Angelman Syndrome and the ATRI:
- Angelman Syndrome (AS) occurs once in every 15,000 live births and exhibits symptoms such as: developmental delay; lack of speech; seizures; inappropriate laughter; and walking and balance disorders.

- ATRI will realize the Angelman Syndrome Foundation's "scientific roadmap," which will help direct its aggressive funding of AS research.

- Short term focus of the roadmap is to fund research that finds treatments that may cure symptoms of AS while continuing ongoing research and clinical trials involving UBE3A, the abnormal gene in AS patients.

- Research funding will also focus on new therapies for symptoms, pharmaceuticals, biological agents, adaptive devices, surgical and diagnostic procedures.

- An emphasis on adult AS patients will extend the scope of clinical trials to include a wide age group and investigate and advance life and self-help skills, vocational training, and access to community programs and health services.

- ATRI will allow scientific members to conduct Web-based meetings and symposiums, and convene as necessary to discuss research progress and activities.

- Since AS shares symptoms with several other disorders, including autism, cerebral palsy, epilepsy, Rett Syndrome, and Prader-Willi Syndrome, any progress toward treating and curing symptoms has the potential to positively affect more than 12 million people.

Quotes Attributed to Michael D. Ehlers, M.D., Ph.D., Department of Neurobiology at Duke University Medical Center:
- "The creation of the Angelman Treatment and Research Institute is exciting and timely.
- "The priorities as established by the ATRI are right on in recognizing the continued need for expanding our fundamental knowledge of UBE3A and its role in brain development and function."
- "The Angelman Syndrome Foundation is to be applauded for having the vision to recognize the critical importance of basic research and in setting this research on a trajectory toward a cure."
- "I see a future of great opportunity and advance in neurodevelopmental disorders with Angelman Syndrome and the ATRI leading the way."

Quotes Attributed to Eileen Braun, Angelman Syndrome Foundation Executive Director
- The Angelman Syndrome Foundation is committing $125,000 in seed funding to start ATRI with an ultimate goal of raising $2 million within two years.
- Funding will be used to implement program goals while the Angelman Syndrome Foundation's Scientific Advisory Committee will continue administering grant reviews and making funding recommendations for innovative research.

Related Links:
Angelman Syndrome Foundation Web site
Researcher Endorsements of the ATRI
Angelman Syndrome Foundation Videos

About Angelman Syndrome:
Identified by Dr. Harry Angelman, AS occurs once in every 15,000 live births and exhibits symptoms such as: developmental delay; lack of speech; seizures; inappropriate laughter; and walking and balance disorders. It is a life-long neuro-genetic disorder usually identified in patients between two and five years old. AS is often misdiagnosed as autism and a cure has not yet been developed.

About Angelman Syndrome Foundation:
The Angelman Syndrome Foundation, the leading resource for AS information, support and AS research funding was founded more than 20 years ago with the mission of advancing the awareness and treatment of AS through education and information, research and support for individuals with AS, their families and other concerned parties. Since 1996 the Angelman Syndrome Foundation has funded 51 research grants totaling over $2.5 million. The Angelman Syndrome Foundation has awarded a majority of these funds ($2.2 million) beginning in 2005. In November 2008, the Angelman Syndrome Foundation received Charity Navigator's 4-star rating for sound fiscal management. Only a quarter of all charities evaluated by Charity Navigator receive this distinction of demonstrating the ability to efficiently manage and grow its finances.

###

Read the full story at http://www.prweb.com/releases/2009/08/prweb2706254.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Angelman Syndrome Foundation Takes Major Step Toward Furthering Research Efforts
2. Diabetes appears to increase risk of death for patients with acute coronary syndromes
3. Eye-staining technique offers early detection for dry eye syndrome
4. Pollen, Fruits, Veggies Help Trigger Oral Allergy Syndrome
5. Treating depression may improve recovery of heart rate variability following coronary syndromes
6. Stem cell research produces a key discovery for Fragile X Syndrome
7. Metabolic syndrome heightens risk for development of uric-acid kidney stones
8. Stomach Virus a Culprit in Chronic Fatigue Syndrome
9. Chronic fatigue syndrome linked to stomach virus
10. Toward a faster prenatal test for Down syndrome
11. Brain Defect Helps Drive Fragile X Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Angelman Syndrome Foundation Takes Major Step Toward Furthering Research Efforts
(Date:7/18/2017)... ... July 18, 2017 , ... ... commercialization, has just announced two more sessions of its “From the Helm” Webinar ... management activities. Led by David Cronin, Cognition’s CEO, the half-hour public webinars will ...
(Date:7/18/2017)... PA (PRWEB) , ... July 18, 2017 , ... An ... control excessive sweating. "Due to menopause, I have frequent hot flashes, and I suffer ... effective but inconspicuous way to keep cool while out and about." INSTA-FAN meets that ...
(Date:7/18/2017)... (PRWEB) , ... July 18, 2017 , ... FCPX LUT ... cooler tones any media. FCPX LUT Berlin includes 60 different color-grade presets, giving FCPX ... distorted looks, vignettes and blurs to emphasize each subject, plus much more. FCPX LUT ...
(Date:7/17/2017)... Greenwich, Connecticut (PRWEB) , ... July 17, 2017 ... ... not too late for parents and camp staff to ensure children are protected ... of Lyme disease this year, children are at an increased risk not only ...
(Date:7/17/2017)... ... 17, 2017 , ... Jordan Search Consultants (JSC), a national ... for Springfield Clinic’s Chief Executive Officer (CEO) in Springfield, IL. Working with JSC ... with more than 30 years of experience, as the new CEO. , ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... pharmaceutical company focused on the development of oral drug delivery ... Israel Securities Authority to dual-list its common stock on the ... trading on the TASE on July 12, 2017 under the ... Company, it is expected that Oramed will be included in ...
(Date:6/30/2017)... , June 30, 2017  AVACEN Medical (AVACEN) announced the ... The research describes the use of its AVACEN Treatment Method ... suffering from fibromyalgia. ... AVACEN Medical ... characterized by chronic widespread pain. It affects approximately 200 to 400 million ...
(Date:6/20/2017)... , June 19, 2017  Hill-Rom Holdings, Inc. (NYSE: ... call and webcast on Friday, July 28, 2017, beginning at ... Call Audio Only Dial-in information: To participate in the conference ... dial into the call at least 10 minutes prior to ... is 34090339.  Webcast: ...
Breaking Medicine Technology: